Jorge Nadal

ORCID: 0000-0001-6266-4070 · 1 paper in corpus

article 2024

Abstract PO5-02-03: Does the recommendation of adjuvant CDK4/6 inhibitors implicate more ovarian suppression in premenopausal patients? A real-world study of a public and a private Argentinean institution

·doi:10.1158/1538-7445.sabcs23-po5-02-03

Abstract Introduction The recently published NATALEE trial has reported an increase of invasive disease free survival with the addition of ribociclib to hormone therapy during 3 years. Given the fact that aromatase inhibitors are required a…